Company Legal Name
Latest Valuation
Founded Year
Headquarter
Inito develops at-home hormone testing devices and mobile applications that enable women to track fertility and confirm ovulation through precise hormone monitoring. The Houston-based company differentiates itself in the femtech market by providing laboratory-quality hormone analysis in a consumer-friendly format, allowing users to measure multiple fertility hormones from home. Inito's technology addresses the growing demand for personalized reproductive health solutions, offering women greater control and insight into their fertility cycles. The company continues to focus on expanding its hormone testing capabilities and enhancing its digital platform to serve the evolving needs of women seeking comprehensive fertility tracking solutions.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





